CRVO Lucentis Study

Who is the sponsor?
California Retina Research Foundation

Who are the patients?
Male or female patients over the age of eighteen years with CRVO The participating doctor will evaluate the patient to determine his/her eligibility into the study in accordance with the Study Eligibility and Exclusion Criteria.

How long is the trial?
Patients were monitored for 3 years.

When did participation agreement start at our site?
January 2006

What is the enrollment goal for the sponsor?
Twenty patients.

What is this study investigating?
This is a Phase I study using Intravitreal ranibizumab (Lucentis) in the treatment of macular edema associated with perfused central retinal vein occlusive disease (CRVO).

How is the treatment administered?
Ranibizumab is administered as an injection into the eye.